C35H54N7O15.Gd
Neat
812.85 157.25
Gadopiclenol; 933983-75-6; S276568KOY; ELUCIREM; P03277; WHO 10744; P-03277; (alpha3, alpha6, alpha9-Tris(3-((2, 3-dihydroxypropyl)amino)-3-oxopropyl)-3, 6, 9, 15-tetraazabicyclo(9.3.1)pentadeca-1(15), 11, 13-triene-3, 6, 9-triacetato(3-)-kappaN3, kappaN6, kappaN9, kappaN15, kappaO3, kappaO6, kappaO9)gadolinium; gadopiclenolum; Vueway; RefChem:57320; GBCA P03277; P 03277; Gadolinium-based Magnetic Resonance Contrast Agent P03277; 3, 6, 9, 15-Tetraazabicyclo(9.3.1)pentadeca-1(15), 11, 13-triene-3, 6, 9-triacetic acid, alpha, alpha', alpha''-tris(3-((2, 3-dihydroxypropyl)amino)-3-oxopropyl)-, gadolinium salt (1:1); Gadopiclenol [USAN]; UNII-S276568KOY; 2-[3, 9-bis[1-carboxylato-4-(2, 3-dihydroxypropylamino)-4-oxobutyl]-3, 6, 9, 15-tetrazabicyclo[9.3.1]pentadeca-1(15), 11, 13-trien-6-yl]-5-(2 and 3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+); Elucirem (TN); Gadopiclenol [WHO-DD]
2-[3, 9-bis[1-carboxylato-4-(2, 3-dihydroxypropylamino)-4-oxobutyl]-3, 6, 9, 15-tetrazabicyclo[9.3.1]pentadeca-1(15), 11, 13-trien-6-yl]-5-(2 and 3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+)
InChI=1S/C35H57N7O15.Gd/c43-19-24(46)14-36-30(49)7-4-27(33(52)53)40-10-12-41(28(34(54)55)5-8-31(50)37-15-25(47)20-44)17-22-2-1-3-23(39-22)18-42(13-11-40)29(35(56)57)6-9-32(51)38-16-26(48)21-45;/h1-3,24-29,43-48H,4-21H2,(H,36,49)(H,37,50)(H,38,51)(H,52,53)(H,54,55)(H,56,57);/q;+3/p-3